共 50 条
- [1] Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS)JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 201S - 201SGarcia-Manero, GIssa, JPCortes, JKoller, CO'brien, SEstey, ECanalli, AAChiao, JRichon, VKantarjian, H
- [2] Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromesBLOOD, 2008, 111 (03) : 1060 - 1066Garcia-Manero, GuillermoYang, HuiBueso-Ramos, CarlosFerrajoli, AlessandraCortes, JorgeWierda, William G.Faderl, StefanKoller, CharlesMorris, GailRosner, GaryLoboda, AndreyFantin, Valeria R.Randolph, Sophia S.Hardwick, James S.Reilly, John F.Chen, CongRicker, Justin L.Secrist, J. PaulRichon, Victoria M.Frankel, Stanley R.Kantarjian, Hagop M.
- [3] Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myelomaLEUKEMIA & LYMPHOMA, 2008, 49 (03) : 502 - 507Richardson, PaulMitsiades, ConstantineColson, KathleenReilly, EileenMcbride, LauraChiao, JudySun, LindaRicker, JustinRizvi, SyedOerth, CarolAtkins, BarbaraFearen, IvyAnderson, KennethSiegel, David
- [4] Phase I study of sapacitabine, an oral nucleoside analogue, in patients with advanced Leukemias or Myelodysplastic syndromes (MDS)BLOOD, 2007, 110 (11) : 270A - 270AKantarjian, HagopGarcia-Manero, GuillermoFaderl, StefanCortes, JorgeEstrov, ZeevBoone, PatriciaStuart, IainWestwood, RobertGreen, SimonChiao, Judy H.Plunkett, Willilam
- [5] Phase I trial of oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myelomaBLOOD, 2007, 110 (11) : 355A - 355AWeber, Donna M.Jagannath, SundarMazumder, AmitabhaSobecks, RonaldSchiller, Gary J.Gavino, MariaSumbler, ChantelleMcFadden, CarrieChen, CongRicker, Justin L.Rizvi, SyedOerth, CarolBrownell, PatriciaHusein, Mohamad A.
- [6] Final results of a phase I trial of oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myelomaBLOOD, 2007, 110 (11) : 357A - 357ARichardson, Paul G.Mitsiades, Constantine S.Colson, KathleenReilly, EileenMcBride, LauraChiao, JudySun, LindaRicker, Justin L.Rizvi, SyedOerth, CarolAtkins, BarbaraFearen, IvyAnderson, Kenneth C.Siegel, David S.
- [7] Phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients (pts) with non-Hodgkin lymphoma (NHL) in JapanJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Tobinai, K.Watanabe, T.Kobayashi, Y.Yamasaki, S.Morita-Hoshi, Y.Yokoyama, H.Morishima, Y.Kato, H.Frankel, S. R.Otsuki, T.
- [8] Clinical responses to oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) are associated with specific gene expression signatures in patients with advanced leukemias: Results of a phase I trial.BLOOD, 2006, 108 (11) : 657A - 657ALoboda, AndreyFantin, Valeria R.Bueso-Ramos, Carlos E.Randolph, SophiaHardwick, James S.Ricker, Justin L.Richon, Victoria M.Issa, Jean-PierreKantarjian, Hagop M.Frankel, Stanley R.Garcia-Manero, Guillermo
- [9] Phase I study of sapacitabine, an oral nucleoside analogue, in patients with advanced leukemias or myelodysplastic syndromesJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Plunkett, W.Garcia-Manero, G.Faderl, S.Cortes, J.Boone, P.Hilbe, C.Green, S.Chiao, J. H.Kantarjian, H.
- [10] Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancerJOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) : 3923 - 3931Kelly, WKO'Connor, OAKrug, LMChiao, JHHeaney, MCurley, TMacGregore-Cortelli, BTong, WSecrist, JPSchwartz, LRichardson, SChu, EOlgac, SMarks, PAScher, HRichon, VM